About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Daily Archives: April 21, 2010
Advisory Committee Transparency Update – FDA and EMEA
In the United States, new medicines are considered for approval by various consultant committees that the FDA uses to help assess an application for approval. In the European Union, human medicines are considered for approval by the European Medicines Agency … Continue reading
Posted in Uncategorized
Comments Off on Advisory Committee Transparency Update – FDA and EMEA